ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "DMARDs"

  • Abstract Number: 2026 • 2014 ACR/ARHP Annual Meeting

    Treatment Delays and Worse Outcomes Associated with Lower Socioeconomic Status in Rheumatoid Arthritis

    Emily Molina1, Jose Felix Restrepo2, Inmaculada del Rincon1, Daniel Battafarano3 and Agustin Escalante4, 1Rheumatology, University of Texas Health Science Center, San Antonio, TX, 2Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 3Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, 4Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX

    Treatment Delays and Worse Outcomes Associated with Low Socioeconomic Status in Rheumatoid ArthritisBackground/Purpose: Prompt and routine care in rheumatoid arthritis (RA) is critical for best…
  • Abstract Number: 493 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD

    C. Charles-Schoeman1, Gerd Burmester2, P. Nash3, C.a.F. Zerbini4, S. Anway5, K. Kwok6, T. Hendrikx7, E. Bananis8 and Roy Fleischmann9, 1University of California, Los Angeles, CA, 2Charité – University Medicine Berlin, Berlin, Germany, 3Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, 4Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY, 7Pfizer BV, Capelle aan den IJssel, Netherlands, 8Pfizer Inc, Collegeville, PA, 9Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the efficacy and safety of tofacitinib 5…
  • Abstract Number: 2973 • 2014 ACR/ARHP Annual Meeting

    The Multi-Biomarker Disease Activity Score As a Predictor of Radiographic Progression in a Registry of Patients with Rheumatoid Arthritis

    Eric H. Sasso1, George Wu2, CC Hwang2, Michael E. Weinblatt3, Nancy A. Shadick4, Claire Alexander5 and Oscar Segurado1, 1Crescendo Bioscience Inc., South San Francisco, CA, 2Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, 3Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, 4Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, 5Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA

    Background/Purpose This study evaluated the association between baseline disease activity, as assessed with the multi-biomarker disease activity (MBDA) blood test, CRP or clinical measures, and…
  • Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting

    Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses

    Dirkjan van Schaardenburg1, Mairead Murphy2, Yuan Gui2, Samina Turk3, Walter P. Maksymowych4 and Anthony Marotta5, 1Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, 2Augurex Life Sciences Corp., North Vancouver, BC, Canada, 3Reade, Amsterdam, Netherlands, 4Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, 51423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada

    Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
  • Abstract Number: 461 • 2014 ACR/ARHP Annual Meeting

    Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs

    P. Bird1, W. Bensen2, B. El-Zorkany3, J. Kaine4, B.H. Manapat-Reyes5, V. Pascual-Ramos6, D. Witcombe7, A. Anisfeld8, K. Soma9, R. Zhang9 and K. Thirunavukkarasu7, 1Combined Rheumatology Practice, Sydney, Australia, 2St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada, 3Department of Rheumatology, Cairo University, Cairo, Egypt, 4Sarasota Arthritis Research Center, Sarasota, FL, 5Section of Rheumatology, Department of Medicine, University of the Philippines - Philippine General Hospital, Manila, Philippines, 6Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 7Pfizer Australia, Sydney, Australia, 8Pfizer Inc, New York, NY, 9Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib has been approved in the US and other countries at the recommended dose 5 mg BID in patients (pts) with rheumatoid arthritis (RA) and…
  • Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting

    Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis

    Barry J. Sheane1, Arane Thavaneswaran2, Dafna D. Gladman2 and Vinod Chandran2, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
  • Abstract Number: 1871 • 2014 ACR/ARHP Annual Meeting

    Puberty and Disease Activity in JIA

    Philomine A. van Pelt1, Aike.a. Kruize2, Anita C.S. Hokken-Koelega3, Radboud JEM Dolhain4, Johannes WJ Bijlsma5 and Nico M. Wulffraat6, 1Rheumatology, Erasmus MC, Rotterdam, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, 4Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 5Dept of Rheumatology and Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, 6Paediatric Immunology, University Medical Centre Utrecht, Utrecht, Netherlands

    Background/Purpose Delayed puberty and decreased final length has been reported in chronic diseases like Crohn's disease and JIA with a disease onset at prepubertal age.…
  • Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting

    Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study

    Christos E. Lampropoulos1, Philippos Orfanos2, Vasiliki-Kalliopi Bournia3, Theofilos P. Karatsourakis4, Clio P. Mavragani5, Dimitrios Pikazis4, Menelaos N. Manoussakis6, Athanasios G. Tzioufas4, Haralampos M. Moutsopoulos7 and Panayiotis G. Vlachoyiannopoulos3, 1Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 2Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, 3First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 4Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 5Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, 6Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, 7Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
  • Abstract Number: 2902 • 2014 ACR/ARHP Annual Meeting

    The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care

    Kirsten Minden1, Jens Klotsche2, Martina Niewerth2, Angela Zink3 and Gerd Horneff4, 1Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, 2Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, 3German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 4Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany

    Background/Purpose A minority of patients with polyarticular JIA enter adulthood in drug free remission. Thus, patients are in need of care beyond adolescence. There is…
  • Abstract Number: 1527 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison

    Laura Sawyer1, Stacey Chang1, Alex Diamantopoulos2 and Fred Dejonckheere3, 1Symmetron Limited, London, United Kingdom, 2Symmetron Limited, Herts, United Kingdom, 3F. Hoffmann-La Roche, Basel, Switzerland

    Background/Purpose: To date, no head-to-head trials have been conducted comparing the efficacy of biologic treatments for early active rheumatoid arthritis (ERA). Here, we evaluated the…
  • Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting

    Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials

    Richard Conway1, Candice Low2, Robert J. Coughlan1, Martin O'Donnell3 and John J. Carey1, 1Rheumatology, Galway University Hospitals, Galway, Ireland, 2Medicine, St. James Hospital, Dublin, Ireland, 3Clinical Research Facility, Galway University Hospitals, Galway, Ireland

    Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…
  • Abstract Number: 2265 • 2013 ACR/ARHP Annual Meeting

    Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)

    Rieke Alten1, Robert Holt2, Amy Grahn3, Patricia Rice4, Jeffery Kent2, Frank Buttgereit5 and Allan Gibofsky6, 1Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, 2Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, 3Clinical Development, Horizon Pharma, Inc, Deerfield, IL, 4Statistics, CliniRx Research, Naperville, IL, 5Charité - Universitätsmedizin Berlin, Berlin, Germany, 6Medicine and Public Health, Hospital for Special Surgery, New York, NY

    Background/Purpose:    A surge in nocturnal inflammatory cytokines causing morning stiffness (MS) is recognized as a therapeutic target in RA. MS has been underappreciated in…
  • Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting

    Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study

    Zaki AbouZahr1, Andrew Spiegelman2, Maria Cantu3 and Bernard Ng4, 1Baylor College of Medicine, Houston, TX, 2Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, 3Baylor College Of Medicine, Houston, TX, 4Michael E. DeBakey VA Medical Center, Houston, TX

    Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
  • Abstract Number: 1913 • 2013 ACR/ARHP Annual Meeting

    Expectations RA Patients Have For Their Treatment – A Comparison Of Clinical Results For Biologic and Disease-Modifying Anti-Rheumatic Drug Treated Patients Using Multiple Medical Cohorts

    Tsukasa Matsubara1,2, Hiroaki Matsuno2, Tomomaro Izumihara2, Yuichi Takahashi2, Akira Sagawa2, Motohiro Oribe2, Eisuke Shono2, Kensuke Kume2, Masanori Adachi2, Yuichi Nishioka2, Nobumasa Miyake2, Keisuke Hashimoto2, Toshikaki Miyamoto2, Shigeto Kiyokawa2, Tomohiko Yoshida2, Syoichi Kondo2, Yoshiki Shiohira2, Takanori Azuma2, Yukio Sato2, Masaaki Yoshida2, Kenji Mannami2, Akihiko Nakamura2, Yasuhiko Hirabarashi2, Keiko Funahashi3 and James E. Middleton4, 1Department of Orthopedics, Matsubara Mayflower Hospital, Kato, Japan, 2Japanese Clinician's Biologic Research Group, Kobe, Japan, 3Department of Clinical Research, Matsubara Mayflower Hospital, Kato, Japan, 4Research Institute of Joint Diseases, Kobe, Japan

    Background/Purpose: Treat to Target (T2T) primary principal - “The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist”. Japan…
  • Abstract Number: 480 • 2013 ACR/ARHP Annual Meeting

    Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis

    Mária Filková1, Borbala Aradi2, Ladislav Senolt3, Klara Prajzlerova4, Serena Vettori2, Herman F. Mann5, Jiri Vencovsky4, K. Pavelka6, Beat A. Michel7, Renate E Gay2, Steffen Gay2 and Astrid Jüngel2, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 2Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 4Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 6Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, 7Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: The altered expression of cellular miRNAs in the immune and resident cells involved in the pathogenesis of rheumatoid arthritis (RA) has been shown to…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology